HK1210825A1 - Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk - Google Patents

Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk

Info

Publication number
HK1210825A1
HK1210825A1 HK15111491.4A HK15111491A HK1210825A1 HK 1210825 A1 HK1210825 A1 HK 1210825A1 HK 15111491 A HK15111491 A HK 15111491A HK 1210825 A1 HK1210825 A1 HK 1210825A1
Authority
HK
Hong Kong
Prior art keywords
biguanides
statins
compositions
further agents
cardiometabolic risk
Prior art date
Application number
HK15111491.4A
Other languages
Chinese (zh)
Inventor
Alain D Baron
Mark S Fineman
Nigel R A Beeley
Original Assignee
Elcelyx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/547,022 external-priority patent/US8796338B2/en
Priority claimed from US13/734,966 external-priority patent/US9211263B2/en
Application filed by Elcelyx Therapeutics Inc filed Critical Elcelyx Therapeutics Inc
Publication of HK1210825A1 publication Critical patent/HK1210825A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HK15111491.4A 2012-07-11 2015-11-20 Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk HK1210825A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/547,022 US8796338B2 (en) 2011-01-07 2012-07-11 Biguanide compositions and methods of treating metabolic disorders
US13/734,966 US9211263B2 (en) 2012-01-06 2013-01-05 Compositions and methods of treating metabolic disorders
PCT/US2013/050142 WO2014011926A1 (en) 2012-07-11 2013-07-11 Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk

Publications (1)

Publication Number Publication Date
HK1210825A1 true HK1210825A1 (en) 2016-05-06

Family

ID=48833086

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15111491.4A HK1210825A1 (en) 2012-07-11 2015-11-20 Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk

Country Status (9)

Country Link
EP (1) EP2872127A1 (en)
JP (2) JP2015522080A (en)
CN (1) CN104780915A (en)
AR (1) AR091739A1 (en)
AU (1) AU2013290100A1 (en)
CA (1) CA2878625A1 (en)
HK (1) HK1210825A1 (en)
IL (1) IL236647A0 (en)
WO (1) WO2014011926A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2395983B1 (en) 2009-02-13 2020-04-08 Boehringer Ingelheim International GmbH Pharmaceutical composition comprisng a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
AR085689A1 (en) 2011-03-07 2013-10-23 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITIONS OF METFORMIN, LINAGLIPTINE AND AN SGLT-2 INHIBITOR
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
PT2981271T (en) 2013-04-05 2019-02-19 Boehringer Ingelheim Int Therapeutic uses of empagliflozin
AU2014255727B2 (en) 2013-04-18 2019-07-25 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20210251985A1 (en) * 2017-12-26 2021-08-19 Sunshine Lake Pharma Co., Ltd. Lurasidone solid dispersion and preparation method thereof

Family Cites Families (275)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
JPS58403B2 (en) 1975-07-24 1983-01-06 武田薬品工業株式会社 L- Ascorbine Sanseizaino Seizouhou
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5135757A (en) 1988-09-19 1992-08-04 Edward Mendell Co., Inc. Compressible sustained release solid dosage forms
IT1229203B (en) 1989-03-22 1991-07-25 Bioresearch Spa USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
FR2704146B1 (en) 1993-04-19 1995-07-13 Cripdom Microcapsules of acetylsalicylic acid with controlled release.
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
IT1270594B (en) 1994-07-07 1997-05-07 Recordati Chem Pharm CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN
FR2725623A1 (en) 1994-10-18 1996-04-19 Flamel Tech Sa MEDICINAL AND / OR NUTRITION MICROCAPSULES FOR PER OS ADMINISTRATION
DK0973534T3 (en) 1997-04-15 2007-03-12 Csir Plant extracts with appetite suppressant activity
US5891919A (en) 1997-09-19 1999-04-06 Burlington Bio-Medical & Scientific Corp. Denatonium capsaicinate and methods of producing the same
US6180365B1 (en) 1998-11-06 2001-01-30 Smithkline Beecham Corporation Polynucleotide encoding a Mouse 7-transmembrane GPR43 receptor
ITMI991316A1 (en) 1999-06-14 2000-12-14 Cip Ninety Two 92 S A ORAL PHARMACEUTICAL COMPOSITIONS WITH MODIFIED RELEASE OF MESALAZINE
IL132313A0 (en) 1999-10-11 2001-03-19 Yeda Res & Dev Leptin assay
US20030113810A1 (en) 2000-02-18 2003-06-19 Alan Wise Novel assay
US20110217394A1 (en) 2000-12-05 2011-09-08 Brett Justin West Iridoid Based Formulations
AU2002307217A1 (en) 2001-03-28 2002-10-15 University Of South Florida Materials and methods for treatment of cancer and identification of anti-cancer compounds
US8030008B2 (en) 2001-04-05 2011-10-04 Senomyx, Inc. Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators
JP4360915B2 (en) 2002-01-07 2009-11-11 ユーロスクリーン・ソシエテ・アノニム G protein-coupled receptor GPR43 ligand and use thereof
US20030171407A1 (en) * 2002-03-07 2003-09-11 Upsher-Smith Laboratories, Inc. Composition for reducing blood glucose and cholesterol
US20060019346A1 (en) 2002-07-29 2006-01-26 Senomyx, Inc. Identification of a novel bitter taste receptor T2R76 that specifically responds to brucine and prop bitter ligands
CA2494281A1 (en) * 2002-08-02 2004-02-12 Penwest Pharmaceuticals Company Sustained release formulations of metformin
WO2004033431A2 (en) 2002-10-04 2004-04-22 Arena Pharmaceuticals, Inc. Hydroxypyrazoles for use against metabolic-related disorders
AU2003300014A1 (en) 2002-10-10 2004-05-04 Arena Pharmaceuticals, Inc. 5-substituted 2h-pyrazone-3-carboxylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia
WO2004038421A2 (en) 2002-10-25 2004-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human g protein-coupled receptor 41 (gpr41)
AU2003273994A1 (en) 2002-10-25 2004-05-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 43 (gpr43)
EP2385032A1 (en) 2002-11-08 2011-11-09 Takeda Pharmaceutical Company Limited GPR40 Receptor function regulator
CN1413582A (en) * 2002-11-29 2003-04-30 贵州圣济堂制药有限公司 Dimethyldiguanide hydrochloride enteric solubility tablet and its preparation method
AU2003286069A1 (en) 2002-12-18 2004-07-09 Givaudan Sa Chimeric alpha q-gustducin g-proteins
US20060160088A1 (en) 2003-02-17 2006-07-20 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 40 (gpr40)
DE10308504A1 (en) 2003-02-26 2004-09-09 Basf Ag Enzymatic production of (meth) acrylic acid esters
WO2004106276A1 (en) 2003-05-30 2004-12-09 Takeda Pharmaceutical Company Limited Condensed ring compound
CA2528834A1 (en) 2003-06-13 2005-02-10 Arena Pharmaceuticals, Inc. 5-substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor rup25 for the treatment of dyslipidemia and related diseases
WO2005009351A2 (en) 2003-07-17 2005-02-03 Santé International, Inc. Dietary supplement for promoting control of blood-sugar levels and associated pathology in type 2 diabetics
WO2005023766A1 (en) * 2003-09-11 2005-03-17 Biocon Limited Salt of atorvastatin with metformin
WO2005028488A1 (en) 2003-09-12 2005-03-31 Quatrx Pharmaceuticals Co. Heteroaryl phosphinyl and thiophosphinyl compounds for regulation of glucose, triglycerides, and ldl/hdl levels
TWI258478B (en) 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
WO2005051890A1 (en) 2003-11-19 2005-06-09 Smithkline Beecham Corporation Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
DE602004022864D1 (en) 2003-11-21 2009-10-08 Arena Pharm Inc 4-OXO-4,5-DIHYDRO-FURAN-2-CARBOXYLIC ACID AND DERIVATIVES AND METHOD FOR THE TREATMENT OF METABOLISM DISORDERS WITH THESE COMPOUNDS
AU2004309271A1 (en) 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
JP4855777B2 (en) 2003-12-26 2012-01-18 武田薬品工業株式会社 Phenylpropanoic acid derivatives
CA2560111A1 (en) 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited Aminophenylpropanoic acid derivative
JP4859665B2 (en) 2004-03-30 2012-01-25 武田薬品工業株式会社 Alkoxyphenylpropanoic acid derivatives
US8158372B2 (en) 2004-04-20 2012-04-17 Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke Agonists of a bitter taste receptor and uses thereof
JP2007284350A (en) 2004-07-27 2007-11-01 Takeda Chem Ind Ltd Therapeutic agent for diabetes
US20060024335A1 (en) 2004-07-29 2006-02-02 Roger Stier E Oral compositions which mask the bitter taste of a bitter-tasting agent
EP1797435A2 (en) 2004-09-22 2007-06-20 Arena Pharmaceuticals, Inc. Gpr43 and modulators thereof for the treatment of metabolic-related disorders
EP1810677A1 (en) 2004-10-08 2007-07-25 Takeda Pharmaceutical Company Limited Receptor function regulating agent
ES2498972T3 (en) 2004-11-03 2014-09-26 Arena Pharmaceuticals, Inc. GPR41 and its modulators for the treatment of insulin-related disorders
US7829299B2 (en) 2004-11-18 2010-11-09 Deutsches Institut fur Ernahrungforschung Potsdam-Rehbrucke Stiftung des Offentlichen Rechts Agonists of bitter taste receptors and uses thereof
PE20060949A1 (en) 2004-12-23 2006-10-11 Arena Pharm Inc FUSED DERIVATIVES OF PIRAZOLE AS NIACIN RECEPTOR AGONISTS
DOP2006000008A (en) 2005-01-10 2006-08-31 Arena Pharm Inc COMBINED THERAPY FOR THE TREATMENT OF DIABETES AND RELATED AFFECTIONS AND FOR THE TREATMENT OF AFFECTIONS THAT IMPROVE THROUGH AN INCREASE IN THE BLOOD CONCENTRATION OF GLP-1
CN101106991A (en) 2005-01-28 2008-01-16 默克公司 Antidiabetic bicyclic compounds
EP1846379B1 (en) 2005-01-31 2009-08-19 Merck & Co., Inc. Antidiabetic bicyclic compounds
US20060222709A1 (en) * 2005-03-18 2006-10-05 Agi Therapeutics Research Ltd. Metformin methods and formulations for treating chronic constipation
WO2006102653A2 (en) 2005-03-24 2006-09-28 Irm Llc Methods and compositions for treating insulin resistance and obesity-induced diseases
EP1878734A4 (en) 2005-04-28 2010-02-17 Ajinomoto Kk Novel lactam compound
EP1899304A1 (en) 2005-05-23 2008-03-19 Arena Pharmaceuticals, Inc. 5-amino-1h-pyrazole-3-carboxylic acid derivatives as agonists for the g-protein coupled receptor (gpcr) rup38 for the treatment of metabolic-related disorders thereof
US20060269617A1 (en) 2005-05-26 2006-11-30 Suracell, Inc. Supplement compositions and method of use for enhancement of insulin sensitivity
EP1907847A4 (en) 2005-06-22 2009-07-01 Senomyx Inc Identification of human t2r receptors that are activated by bitter molecules in coffee (chlorogenic lactones) and related assays for identifying human bitter taste modulators
US20080299270A1 (en) 2005-07-28 2008-12-04 Nestec S.A. Fat Taste Receptors and Their Methods of Use
EP1916234B1 (en) 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
EP1924709A1 (en) 2005-08-10 2008-05-28 Arena Pharmaceuticals, Inc. Methods for determining probability of an adverse or favorable reaction to a niacin receptor agonist
US8399204B2 (en) 2005-09-02 2013-03-19 Eisai R&D Management Co., Ltd. Method for screening of substance which alter GPR120-mediated cell-stimulating activities
WO2007049050A2 (en) 2005-10-27 2007-05-03 Heptahelix Ab Modulators of gpr40 for the treatment of diabetes
US20070104805A1 (en) 2005-11-01 2007-05-10 Udell Ronald G Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives
JP2007215162A (en) 2006-01-11 2007-08-23 Canon Inc Information processing apparatus, control method thereof, program and recording medium
US20070207227A1 (en) 2006-02-23 2007-09-06 Conopco, Inc., D/B/A Unilever, A Corporation Of New York Appetite suppressant compositions
AU2007235673A1 (en) 2006-04-06 2007-10-18 Prosidion Limited Heterocyclic GPCR agonists
WO2007116404A2 (en) 2006-04-10 2007-10-18 Bar-Ilan University Cucurbitacin glucosides and use thereof in treating cancer
GB0607196D0 (en) 2006-04-11 2006-05-17 Prosidion Ltd G-protein coupled receptor agonists
CA2618488C (en) 2006-04-11 2010-07-13 Arena Pharmaceuticals, Inc. Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
PE20071221A1 (en) 2006-04-11 2007-12-14 Arena Pharm Inc GPR119 RECEPTOR AGONISTS IN METHODS TO INCREASE BONE MASS AND TO TREAT OSTEOPOROSIS AND OTHER CONDITIONS CHARACTERIZED BY LOW BONE MASS, AND COMBINED THERAPY RELATED TO THESE AGONISTS
TW200815377A (en) 2006-04-24 2008-04-01 Astellas Pharma Inc Oxadiazolidinedione compound
JP5271895B2 (en) 2006-05-15 2013-08-21 メルク・シャープ・アンド・ドーム・コーポレーション Antidiabetic bicyclic compounds
WO2007134613A1 (en) 2006-05-24 2007-11-29 Rheoscience A/S Modulation of gpr120 activity in adipocytes/fat tissue
RU2444521C2 (en) 2006-06-27 2012-03-10 Такеда Фармасьютикал Компани Лимитед Condensed cyclic compounds
CA2551706A1 (en) 2006-06-27 2007-12-27 Innovative Life Sciences Corporation Herbal product comprising cinnamon and bitter melon
CN100596277C (en) 2006-07-10 2010-03-31 博仲盛景医药技术（北京）有限公司 Medicinal composition for promoting enterogastric peristalsis
CN101511429A (en) 2006-07-13 2009-08-19 史密丝克莱恩比彻姆公司 Indulines derivatives and gpr119 agonists
CN101505771A (en) 2006-08-17 2009-08-12 荷兰联合利华有限公司 Processes for production of HOODIA plant extracts containing steroidal glycosides
CN101505772A (en) 2006-08-24 2009-08-12 荷兰联合利华有限公司 Process for preparing a composition comprising steroidal glycosides
CA2661371A1 (en) 2006-08-30 2008-03-06 Biovitrum Ab (Publ) Pyrimidine compounds for treating gpr119 related disorders
CN101522702A (en) 2006-09-05 2009-09-02 塞诺米克斯公司 Novel haplotype of human t2r receptor ht2r50 and its use in assays for identifying human bitter taste modulators
AU2007293028B2 (en) 2006-09-07 2012-05-31 Amgen Inc. Heterocyclic GPR40 modulators
WO2008063321A2 (en) 2006-10-13 2008-05-29 Janssen Pharmaceutica N.V. Gpr81-ligand complexes and their preparation and use
CA2667249A1 (en) 2006-10-31 2008-05-08 Merck & Co., Inc. Antidiabetic bicyclic compounds
WO2008054674A2 (en) 2006-10-31 2008-05-08 Merck & Co., Inc. Antidiabetic bicyclic compounds
BRMU8602999U (en) * 2006-11-16 2008-07-08 Walter Junior Santos medicine "rosuvastatin + metformin" in combination form for cardiovascular disease
WO2008058355A2 (en) * 2006-11-16 2008-05-22 Walter Santos Junior Descriptive report of patent of invention of the medicament 'atorvastatin + metformin' in combined form for cardiovascular diseases
CN101190179B (en) * 2006-11-20 2010-05-12 北京利龄恒泰药业有限公司 Enteric medicinal composition for treating diabetes and preparation method thereof
WO2008066131A1 (en) 2006-12-01 2008-06-05 Banyu Pharmaceutical Co., Ltd. Novel phenyl-isoxazol-3-ol derivative
TW200838526A (en) 2006-12-01 2008-10-01 Astellas Pharma Inc Carboxylic acid derivatives
EP2109447B1 (en) * 2007-01-29 2015-06-10 HanAll Biopharma Co., Ltd. N, n- dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same
US20080186971A1 (en) 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
WO2008103500A1 (en) 2007-02-22 2008-08-28 Irm Llc Thiazole derivatives as modulators of g protein-coupled receptors
PT2134704E (en) 2007-03-08 2010-12-13 Irm Llc Compounds and compositions as modulators of gpr119 activity
EP1975611A1 (en) 2007-03-29 2008-10-01 Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke-Stiftung des öffentlichen Rechts- Vertreten durch den Stiftungsvorstand Agonists of bitter taste receptors and uses thereof
EP1975612A1 (en) 2007-03-29 2008-10-01 Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke-Stiftung des öffentlichen Rechts- Vertreten durch den Stiftungsvorstand Agonists of bitter taste receptors and uses thereof
WO2008130514A1 (en) 2007-04-16 2008-10-30 Amgen Inc. Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators
CN102015677A (en) 2007-04-20 2011-04-13 先灵公司 Pyrimidinone derivatives and methods of use thereof
WO2008130615A1 (en) 2007-04-20 2008-10-30 Schering Corporation Tetrahydropyrido[4,3-d]pyrimidinone derivatives and methods of use thereof
WO2008130584A1 (en) 2007-04-20 2008-10-30 Schering Corporation Pyrimidinone derivatives and methods of use thereof
EP2151236A4 (en) 2007-04-26 2013-01-16 Japan Science & Tech Agency G-protein-conjugated receptor agonist
WO2008137436A1 (en) 2007-05-04 2008-11-13 Bristol-Myers Squibb Company [6,5]-bicyclic gpr119 g protein-coupled receptor agonists
US7910583B2 (en) 2007-05-04 2011-03-22 Bristol-Myers Squibb Company [6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor agonists
WO2008144423A2 (en) 2007-05-15 2008-11-27 Medical College Of Georgia Research Institute, Inc. Compositions comprising a gpr109 ligand for treating disorders of the digestive tract and/or cancer
SI2173737T1 (en) 2007-07-17 2012-05-31 Bristol Myers Squibb Co Method for modulating gpr119 g protein-coupled receptor and selected compounds
WO2009014910A2 (en) 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 receptor for the treatment of diabetes and metabolic disorders
US20090042813A1 (en) 2007-08-10 2009-02-12 Sergey Michailovich Melnikov Hoodia extract oil compositions comprising medium chain triglycerides
WO2009033072A1 (en) 2007-09-05 2009-03-12 Raif Tawakol Compositions and methods for controlling cholesterol levels
EP2200609A1 (en) 2007-09-10 2010-06-30 Prosidion Limited Compounds for the treatment of metabolic disorders
WO2009038204A1 (en) 2007-09-17 2009-03-26 Pharma Frontier Co., Ltd. Novel long-chain fatty acid derivative compound and g-protein-coupled receptor agonist containing the compound as active ingredient
EP2197873B1 (en) 2007-09-20 2014-07-16 Irm Llc Compounds and compositions as modulators of gpr119 activity
MX2010003876A (en) 2007-10-10 2010-12-02 Amgen Inc Substituted biphenyl gpr40 modulators.
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
WO2009055331A2 (en) 2007-10-22 2009-04-30 Schering Corporation Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119
JP2011016722A (en) 2007-10-23 2011-01-27 Astellas Pharma Inc Thiazolidinedione compound
US20100316736A1 (en) 2007-10-24 2010-12-16 Desert Labs Agriculture Cooperative Association Ltd. Appetite suppressant
TW200932219A (en) 2007-10-24 2009-08-01 Astellas Pharma Inc Oxadiazolidinedione compound
WO2009058237A1 (en) 2007-10-29 2009-05-07 Merck & Co., Inc. Antidiabetic tricyclic compounds
JP5075211B2 (en) 2008-01-29 2012-11-21 中森製薬株式会社 Pharmaceutical composition
CN102007126A (en) 2008-02-22 2011-04-06 Irm责任有限公司 Compounds and compositions as modulators of gpr119 activity
CN102006870A (en) 2008-02-22 2011-04-06 Irm责任有限公司 Compounds and compositions as modulators of gpr119 activity
AU2009217282A1 (en) 2008-02-22 2009-08-27 Irm Llc Compounds and compositions as modulators of GPR119 activity
WO2009106565A1 (en) 2008-02-27 2009-09-03 Biovitrum Ab (Publ) Agonists of gpr119
WO2009106561A1 (en) 2008-02-27 2009-09-03 Biovitrum Ab (Publ) Pyrazine compounds for treating gpr119 related disorders
WO2009117421A2 (en) 2008-03-17 2009-09-24 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
CA2719507C (en) 2008-03-31 2018-03-27 Metabolex, Inc. Oxymethylene aryl compounds and uses thereof
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
BRPI0911118A2 (en) 2008-04-07 2015-10-06 Irm Llc Compound and Compsions as gpr119 Activity Modulators
WO2009125804A1 (en) 2008-04-09 2009-10-15 武田薬品工業株式会社 Screening method
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
WO2009143049A1 (en) 2008-05-19 2009-11-26 Schering Corporation Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
US9844224B2 (en) 2008-05-23 2017-12-19 Givaudan Sa Bitter alkaloid containing consumables comprising bitter blockers
US20110071198A1 (en) 2008-05-27 2011-03-24 Lefkowitz Robert J Nicotinic acid receptor ligands
CN101695575A (en) * 2008-05-29 2010-04-21 北京奥萨医药研究中心有限公司 Pharmaceutical composition containing statin-type lipid-lowering medicaments, phenformin-type hypoglycemic medicaments and nicotinic acid
EP2298750A4 (en) 2008-06-02 2012-04-25 Msd Kk Novel isoxazole derivative
WO2009150144A1 (en) 2008-06-10 2009-12-17 Inovacia Ab New gpr119modulators
US8546085B2 (en) 2008-06-13 2013-10-01 Givaudan Sa Methods of identifying modulators of the bitter taste receptor TAS2R44
WO2010008739A2 (en) 2008-06-20 2010-01-21 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
GB0812031D0 (en) 2008-07-01 2008-08-06 7Tm Pharma As Thiazole derivatives
GB0812648D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
GB0812649D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
CN102137844B (en) 2008-07-11 2013-05-22 Irm责任有限公司 Compounds and compositions as modulators of GPR119 activity
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
MX2011000664A (en) 2008-07-16 2011-02-24 Schering Corp Bicyclic heterocycle derivatives and use thereof as gpr119 modulators.
JP2012503595A (en) 2008-07-28 2012-02-09 シダンスク ユニバーシティ Compounds for the treatment of metabolic diseases
JPWO2010013849A1 (en) 2008-08-01 2012-01-12 日本ケミファ株式会社 GPR119 agonist
EP2330103B1 (en) 2008-08-29 2015-10-07 Suntory Holdings Limited Novel epigallocatechin gallate tetramer, and vascular endothelial function improver comprising same
EP2329271B1 (en) 2008-08-29 2012-06-20 Givaudan SA Methods to identify modulators
CA2736421A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
WO2010030360A1 (en) 2008-09-11 2010-03-18 Arena Pharmaceuticals, Inc. 3H-IMIDAZO[4,5-b]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS
MX2011003917A (en) 2008-10-15 2011-05-31 Amgen Inc Spirocyclic gpr40 modulators.
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
CN102186825A (en) 2008-10-21 2011-09-14 麦它波莱克斯股份有限公司 Aryl gpr120 receptor agonists and uses thereof
WO2010060198A1 (en) 2008-11-26 2010-06-03 West Central Envirotech Inc. Composition and method for controlling insects
AR074760A1 (en) 2008-12-18 2011-02-09 Metabolex Inc GPR120 RECEIVER AGONISTS AND USES OF THE SAME IN MEDICINES FOR THE TREATMENT OF DIABETES AND METABOLIC SYNDROME.
WO2010074271A1 (en) 2008-12-26 2010-07-01 武田薬品工業株式会社 Therapeutic agent for diabetes
CA2748729A1 (en) 2009-01-03 2010-07-08 Shizuoka Prefecture Public University Corporation Sulfated c-glycoside, method for isolating same and method for synthesizing same
TW201031668A (en) 2009-01-22 2010-09-01 Mitsubishi Tanabe Pharma Corp Novel pyrrolo[2,3-d] pyrimidine compound
US20110312967A1 (en) 2009-01-23 2011-12-22 Schering Corporation Bridged and fused antidiabetic compounds
WO2010085525A1 (en) 2009-01-23 2010-07-29 Schering Corporation Bridged and fused heterocyclic antidiabetic compounds
EP2389369A1 (en) 2009-01-23 2011-11-30 Schering Corporation Pentafluorosulpholane-containing antidiabetic compounds
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
EP2393810A1 (en) 2009-02-05 2011-12-14 Schering Corporation Phthalazine-containing antidiabetic compounds
JP5657518B2 (en) 2009-02-18 2015-01-21 武田薬品工業株式会社 Fused heterocyclic compounds
GB0904285D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904284D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
CA2754523A1 (en) 2009-03-20 2010-09-23 Pfizer Inc. 3-oxa-7-azabicyclo[3.3.1]nonanes
JP2012136438A (en) 2009-04-22 2012-07-19 Astellas Pharma Inc Tetrazole compound
AU2010240142A1 (en) 2009-04-22 2011-11-10 Astellas Pharma Inc. Carboxylic acid compound
JP2012136439A (en) 2009-04-24 2012-07-19 Nippon Chemiphar Co Ltd Diazaspiroalkane derivative
JP2012526097A (en) 2009-05-08 2012-10-25 ファイザー・インク GPR119 regulator
JP2012526096A (en) 2009-05-08 2012-10-25 ファイザー・インク GPR119 regulator
KR20120061063A (en) 2009-06-05 2012-06-12 화이자 인코포레이티드 L-(piperidin-4-yl)-pyrazole derivatives as gpr119 modulators
JP5657578B2 (en) 2009-06-09 2015-01-21 武田薬品工業株式会社 Novel fused ring compounds and uses thereof
AR077642A1 (en) 2009-07-09 2011-09-14 Arena Pharm Inc METABOLISM MODULATORS AND THE TREATMENT OF DISORDERS RELATED TO THE SAME
AR077638A1 (en) 2009-07-15 2011-09-14 Lilly Co Eli COMPOSITE OF (METHANOSULPHONYL -PIPERIDIN) - (ALCOXI-ARIL) -TETRAHIDRO- PYRIDINE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF DIABETES OR OBESITY
EP2460010A1 (en) 2009-07-28 2012-06-06 Deutsches Institut für Ernährungsforschung Potsdam-Rehbrücke Agonists and antagonists of human bitter taste receptor tas2r49 and uses thereof
WO2011014520A2 (en) 2009-07-29 2011-02-03 Irm Llc Compounds and compositions as modulators of gpr119 activity
JPWO2011025006A1 (en) 2009-08-31 2013-01-31 日本ケミファ株式会社 GPR119 agonist
SG178948A1 (en) 2009-09-01 2012-04-27 Catabasis Pharmaceuticals Inc Fatty acid niacin conjugates and their uses
WO2011030139A1 (en) 2009-09-11 2011-03-17 Astrazeneca Ab 4- (pyrimidin-2-yl) -piperazine and 4- (pyrimidin-2-yl) -piperidine derivatives as gpr119 modulators
EP2480551A1 (en) 2009-09-23 2012-08-01 Pfizer Inc. Gpr 119 modulators
WO2011044139A1 (en) 2009-10-05 2011-04-14 Catabasis Pharmaceuticals, Inc. Fatty acid acifran derivatives and their uses
WO2011044136A1 (en) 2009-10-05 2011-04-14 Catabasis Pharmaceuticals, Inc. Fatty acid acipimox derivatives and their uses
US8288404B2 (en) 2009-10-06 2012-10-16 Bristol-Myers Squibb Company Pyrrolidine GPR40 modulators
CA2774573A1 (en) 2009-10-09 2011-04-14 Irm Llc Compounds and compositions as modulators of gpr119 activity
US20120202849A1 (en) * 2009-10-12 2012-08-09 Anil Pareek Pharmaceutical compositions for the treatment/prophylaxis of non-alcoholic fatty liver disease
ES2437921T3 (en) 2009-10-21 2014-01-15 Wisconsin Alumni Research Foundation Method to prevent type 1 diabetes
AU2010313469A1 (en) 2009-10-29 2012-06-07 Merck Sharp & Dohme Corp. Bridged Bicyclic Piperidine Derivatives and methods of use thereof
WO2011052756A1 (en) 2009-10-30 2011-05-05 持田製薬株式会社 Novel 3-hydroxy-5-arylisoxazole derivative
WO2011057110A1 (en) 2009-11-06 2011-05-12 Ruprecht-Karls-Universitat-Heidelberg Gpr109a agonists for the treatment of cerebral ischemia
WO2011055770A1 (en) 2009-11-06 2011-05-12 武田薬品工業株式会社 Fused heterocyclic compound
EP2504342A1 (en) 2009-11-23 2012-10-03 Pfizer Inc. Imidazo-pyrazoles as gpr119 inhibitors
WO2011066137A1 (en) 2009-11-24 2011-06-03 Schering Corporation Substituted biaryl derivatives and methods of use thereof
US20120237456A1 (en) 2009-12-04 2012-09-20 Colgate-Palmolive Company Oral compositions containing extracts of garcinia mangostana l. and related methods
EP2332427A1 (en) 2009-12-07 2011-06-15 Nestec S.A. low caloric fat replacers
WO2011072132A1 (en) 2009-12-09 2011-06-16 The Regents Of The University Of California Methods of treating inflammatory conditions
DK2513053T3 (en) 2009-12-18 2018-01-08 Ogeda Sa PYRROLIDINCARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS OF USE IN TREATMENT OF METABOLIC DISORDERS AS AGONISTS OF G-PROTEIN CONNECTED RECEPTOR 43 (GPR43)
JP2013047188A (en) 2009-12-24 2013-03-07 Nippon Chemiphar Co Ltd Gpr119 agonist
KR20130004262A (en) 2009-12-25 2013-01-09 모찌다 세이야쿠 가부시끼가이샤 Novel 3-hydroxy-5-arylisothiazole derivative
EP2345646A1 (en) 2010-01-14 2011-07-20 InterMed Discovery GmbH Use of tricyclic sesquiterpene lactones in the treatment of obesity and related diseases and non-therapeutic treatable conditions
WO2011092284A1 (en) 2010-01-29 2011-08-04 Euroscreen S.A. Novel amino acid derivatives and their use as gpr43 receptor modulators
JPWO2011093501A1 (en) 2010-02-01 2013-06-06 日本ケミファ株式会社 GPR119 agonist
CN101785763B (en) * 2010-02-04 2011-11-23 贵州天安药业股份有限公司 Metformin hydrochloride enteric-coated sustained release tablet and preparation method thereof
JP2013522279A (en) 2010-03-18 2013-06-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Combination of GPR119 agonist and DDP-IV inhibitor linagliptin for use in the treatment of diabetes and related conditions
US20130023494A1 (en) 2010-04-06 2013-01-24 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
BR112012025590A2 (en) 2010-04-08 2016-06-21 Bristol Myers Squibb Co pyrimidinylpiperidinyloxypyridinone analogues as gpr119 modulators
GB201006166D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB201006167D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
US8940716B2 (en) 2010-05-06 2015-01-27 Bristol-Myers Squibb Company Bicyclic heteroaryl compounds as GPR119 modulators
US8729084B2 (en) 2010-05-06 2014-05-20 Bristol-Myers Squibb Company Benzofuranyl analogues as GPR119 modulators
US8772323B2 (en) 2010-05-07 2014-07-08 Boehringer Ingelheim International Gmbh Benzoxazole- and tetrahydrobenzoxazole-substituted pyridazinones as GPR119 agonists
JP2013530947A (en) 2010-05-17 2013-08-01 アレイ バイオファーマ、インコーポレイテッド Piperidinyl-substituted lactams as GPR119 modulators
WO2011145718A1 (en) 2010-05-21 2011-11-24 田辺三菱製薬株式会社 Novel pyrrolo[2,3-d]pyrimidine compound
TW201202230A (en) 2010-05-24 2012-01-16 Mitsubishi Tanabe Pharma Corp Novel quinazoline compound
US20110293753A1 (en) 2010-05-28 2011-12-01 Louis Bellafiore Tocotrienol Compositions
TW201209054A (en) 2010-05-28 2012-03-01 Prosidion Ltd Novel compounds
WO2011151436A2 (en) 2010-06-04 2011-12-08 Euroscreen S.A. Novel compounds, method for use them and pharmaceutical composition containing them
GB201009873D0 (en) 2010-06-14 2010-07-21 Univ Leuven Kath Method for hydrogenation of isoalpha-acids (isohumulones) to hexahydro-iso-alpha-acids (hexahydro-isohumulones) by using heterogeneous ruthenium
WO2011159297A1 (en) 2010-06-16 2011-12-22 Metabolex, Inc. Gpr120 receptor agonists and uses thereof
WO2011159657A1 (en) 2010-06-18 2011-12-22 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and methods of use thereof
EP2397039A1 (en) 2010-06-21 2011-12-21 Abbott Laboratories Compositions for delaying progression of diabetes using Salacia oblonga extract
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2012006955A1 (en) 2010-07-14 2012-01-19 Zhejiang Beta Pharma Inc. Compounds for treatment of metabolic disorders
WO2012011125A1 (en) 2010-07-23 2012-01-26 Connexios Life Sciences Pvt. Ltd. Agonists of gpr40
KR20120011357A (en) 2010-07-23 2012-02-08 현대약품 주식회사 Substituted pyridinone derivatives and methods for manufacturing the same
WO2012025811A1 (en) 2010-08-23 2012-03-01 Lupin Limited Indolylpyrimidines as modulators of gpr119
CN103221046A (en) 2010-09-17 2013-07-24 阵列生物制药公司 Piperidinyl-substituted lactams as gpr119 modulators
EP3323818A1 (en) 2010-09-22 2018-05-23 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
CN102432598A (en) 2010-09-29 2012-05-02 江苏恒瑞医药股份有限公司 Tricyclic compound, preparation method thereof and pharmaceutical application thereof
WO2012046869A1 (en) 2010-10-08 2012-04-12 持田製薬株式会社 Cyclic amide derivative
DK2625177T3 (en) 2010-10-08 2015-10-12 Cadila Healthcare Ltd New GPR 119 agonists
JP2014001144A (en) 2010-10-08 2014-01-09 Nippon Chemiphar Co Ltd Gpr119 agonist
CN101978956B (en) * 2010-10-13 2012-03-28 北京京丰制药有限公司 Metformin hydrochloride enteric-coated tablets and preparation method thereof
CA2853974C (en) 2010-10-30 2020-11-10 Kindex Therapeutics, Llc Cis 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one derivatives, substantially enantiomerically pure compositions and methods
MA34805B1 (en) 2010-11-23 2014-01-02 Pfizer 4- (5-CYANO-PYRAZOLE-1-YL) -PIPERIDINE DERIVATIVES AS MODULATORS OF GPR119
US9000175B2 (en) 2010-11-26 2015-04-07 Lupin Limited Bicyclic GPR119 modulators
AR084050A1 (en) 2010-12-01 2013-04-17 Boehringer Ingelheim Int INDANILOXIDIHIDROBENZOFURANILACETIC ACIDS
WO2012077655A1 (en) 2010-12-07 2012-06-14 塩野義製薬株式会社 Spiro derivative having gpr119 agonist activity
UY33805A (en) 2010-12-17 2012-07-31 Boehringer Ingelheim Int ? Dihydrobenzofuranyl-piperidinyl, aza-dihydrobenzofuranylpiperidinyl and diaza-dihydrobenzofuranyl-piperidinyl derivatives, pharmaceutical compositions containing them and uses thereof?
EP2661438A4 (en) 2011-01-03 2014-06-11 Hanmi Pharm Ind Co Ltd New bicyclic compound for modulating g protein-coupled receptors
CN103443097A (en) 2011-01-21 2013-12-11 勃林格殷格翰国际有限公司 Fused dihydrofurans as GPR119 modulators for the treatment of diabetes, obesity and related disorders
CN102617548A (en) 2011-01-31 2012-08-01 北京赛林泰医药技术有限公司 Bicycloheteroaryl compounds as GPR Receptor stimulant, compositions and application thereof
TW201309639A (en) 2011-02-17 2013-03-01 Lg Life Sciences Ltd Oxime derivatives as GPR119 agonists
EP2686312B1 (en) 2011-03-14 2016-08-31 Boehringer Ingelheim International GmbH N-cyclopropyl-n-piperidinylbenzamides as gpr119 modulators
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US9499467B2 (en) 2011-04-08 2016-11-22 Caldan Therapeutics Limited Ortho-fluoro substituted compounds for the treatment of metabolic diseases
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
BR112013027883A2 (en) 2011-04-27 2017-08-08 Mochida Pharm Co Ltd new 3-hydroxyisothiazole 1-oxide derivative
JPWO2012147516A1 (en) 2011-04-28 2014-07-28 持田製薬株式会社 Cyclic amide derivative
WO2012154009A2 (en) 2011-05-12 2012-11-15 한국화학연구원 Thienopyrimidine derivatives, pharmaceutically acceptable salts thereof, method for preparing thienopyrimidine derivatives, and pharmaceutical composition containing thienopyrimidine derivatives as active ingredients for preventing or treating diabetes-related diseases
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012168315A1 (en) 2011-06-09 2012-12-13 Boehringer Ingelheim International Gmbh Substituted piperidines as gpr119 modulators for the treatment of metabolic disorders
JP2014159376A (en) 2011-06-17 2014-09-04 Taisho Pharmaceutical Co Ltd Azaspiroalkane compound
CA2841757A1 (en) 2011-07-15 2013-01-24 Etzer Darout Gpr 119 modulators
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
CN102357088A (en) * 2011-10-26 2012-02-22 河北山姆士药业有限公司 Metformin hydrochloride enteric-coated tablet

Also Published As

Publication number Publication date
CN104780915A (en) 2015-07-15
EP2872127A1 (en) 2015-05-20
IL236647A0 (en) 2015-02-26
JP2018087214A (en) 2018-06-07
CA2878625A1 (en) 2014-01-16
JP2015522080A (en) 2015-08-03
AR091739A1 (en) 2015-02-25
WO2014011926A1 (en) 2014-01-16
AU2013290100A1 (en) 2015-01-29

Similar Documents

Publication Publication Date Title
IL238958A0 (en) Glutamase inhibitors, compositions comprising same and uses thereof
IL238959A (en) Glutamase inhibitors, compositions comprising same and uses thereof
IL239568A0 (en) Antimicrobial compositions
IL237625A0 (en) Anti-mcam antibodies, compositions comprising same and uses thereof
IL233154A (en) Compounds, pharmaceutical compositions comprising the same and uses thereof
IL235767A (en) Substituted pyrrolidines, pharmaceutical compositions comprising the same and uses thereof
LT2825699T (en) Fibrous composition
HK1212625A1 (en) Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inflammatory disorder -cxcl9-cxcl10-cxcl11-cxcl13-cxcr3 -cxcr5
IL235585B (en) Ha binding agents, compositions comprising same and uses thereof
IL236463A0 (en) Bifluorodioxalane-amino-benzimidazole compounds, compositions comprising same, processes for producing same and uses thereof
IL235004A0 (en) Anti-fgfr2 antibodies, compositions comprising same and uses thereof
HK1210825A1 (en) Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
IL233824A (en) 1h-indazole-3-carboxamide compounds, compositions comprising them and uses thereof
HK1212156A1 (en) Antimicrobial composition
HK1216250A1 (en) 8-hydroxy-dihydroergotamine compounds and compositions 8--
IL236712A0 (en) Di-and tri-heteroaryl derivatives, compositions comprising same and uses thereof
HK1206266A1 (en) Methods and compositions for the prevention and treatment neuropathy
IL280316B (en) Bolaamphiphilic compounds, compositions and uses thereof
IL237542A0 (en) Bolaamphiphilic compounds, compositions and uses thereof
IL237540A0 (en) Bolaamphiphilic compounds, compositions and uses thereof
IL237538B (en) Bolaamphiphilic compounds, compositions and uses thereof
EP2838365A4 (en) Antimicrobial compositions and uses thereof
EP2802565A4 (en) Compounds, compositions and associated methods comprising 3-aryl quinolines
IL237539A0 (en) Bolaamphiphilic compounds, compositions and uses thereof
ZA201408903B (en) Antimicrobial composition